Lilly Plots Path for Cholesterol Pill After Strong Mid-Stage
Nov 19, 2024 · Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop in the biomarker after 12 weeks.
Texas Biomedical Research Institute enters landmark ... - BioSpace
Oct 29, 2024 · Texas Biomed now part of global “100 Days Mission” effort aimed at preventing and quickly containing infectious disease outbreaks through accelerated vaccine development SAN ANTONIO, Oct. 28, 2024 /PRNewswire/ -- Texas Biomedical Research Institute (Texas Biomed) has entered a global partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). The five-year agreement will ...
Kodiak Sciences to Present at Innovate Retina 2024 - BioSpace
Oct 15, 2024 · PALO ALTO, Calif., Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois. Presentation and Panel ...
Phase III Clinical Trials - BioSpace
4 days ago · Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that could position them as new standards of care in certain subtypes of metastatic colorectal cancer.
Ionis’ Tryngolza Becomes First FDA-Approved Therapy for
Dec 20, 2024 · The FDA on Thursday cleared the U.S.’s first treatment for the rare disease familial chylomicronemia syndrome: Ionis Pharmaceuticals’ RNA-targeting therapy olezarsen, which will be marketed under the brand name Tryngolza. Ionis expects to make Tryngolza available in the U.S. before the year ends, according to its announcement. Affecting up to around 3,000 people in the U.S., familial ...
AusperBio to Present Ongoing AHB-137 Clinical Data in Late
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- AusperBio Therapeutic, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that new clinical data from its lead candidate AHB-137, an antisense oligonucleotide (ASO) therapeutic, will be featured in a late-breaking oral presentation at the 2024 Liver Meeting®, organized by the American ...
Study Illuminates Possible Link Between COVID-19 and ... - BioSpace
Dec 19, 2021 · The findings may have far-reaching consequences for any COVID-19 vaccines in development that are based upon targeting the well-conserved SARS-CoV-2 nucleocapsid (N-) protein.
Vertex Unveils Full Phase III Data for Non-Opioid Pain ... - BioSpace
Oct 21, 2024 · Vertex Pharmaceuticals ’ investigational non-opioid pain therapy suzetrigine has a cleaner safety profile than standard pain relief medicines and even placebo, according to full Phase III data presented over the weekend at the 2024 annual meeting of the American Society of Anesthesiologists in Philadelphia. In study participants who were undergoing abdominoplasty—more commonly known as a ...
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market
Nov 21, 2024 · Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
Mesoblast Wins First Mesenchymal Stromal Cell Therapy FDA
Dec 19, 2024 · The FDA on Wednesday signed off on Mesoblast Limited’s remestemcel-L, now to be marketed as Ryoncil, for the treatment of steroid-refractory acute graft-versus-host disease in patients 2 months of age and up. According to the Australian biotech, Ryoncil is the “first mesenchymal stromal cell (MSC) therapy” approved in the U.S. Graft-versus-host disease (GVHD) is a complication that ...